Inactive Instrument

BioSpecifics Technologies Corp.

Equities

BSTC

US0909311062

Biotechnology & Medical Research

Biospecifics Technologies Corp. Reports Earnings Results for the First Quarter Ended March 31, 2019

May 10, 2019 at 08:01 am EDT

BioSpecifics Technologies Corp. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced total revenue was USD 8.129 million compared to USD 7.089 million a year ago. Operating income was USD 5.072 million compared to USD 4.824 million a year ago. Net income was USD 4.416 million compared to USD 3.978 million a year ago. Basic earnings per share was USD 0.61 compared to USD 0.55 a year ago. Diluted earnings per share was USD 0.6 compared to USD 0.54 a year ago.

Latest news about BioSpecifics Technologies Corp.

Fourth Amended Joint Reorganization Plan Approved for Endo International plc	Mar. 22	CI
Fourth Amended Joint Reorganization Plan Filed by Endo International plc	Mar. 18	CI
Third Amended Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	Feb. 20	CI
Motion for Exclusivity Period Extension Approved For Endo International plc	Jan. 24	CI
Combined Hearing for Disclosure Statement and Plan Approved for Endo International plc	Jan. 12	CI
Second Amended Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	Jan. 09	CI
First Amended Reorganization Plan and Disclosure Statement Filed by Endo International plc	Jan. 05	CI
Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	Dec. 18	CI
Third Motion for Exclusivity Period Extension Approved For Endo International plc	Nov. 15	CI
Second Motion for Exclusivity Period Extension Approved For Endo International plc	23-07-31	CI
Two Affiliate Companies Joined Endo International plc Bankruptcy	23-05-25	CI
First Motion for Exclusivity Period Extension Approved For Endo International plc	23-04-03	CI
First Motion for Exclusivity Period Extension Filed by Endo International plc	22-12-13	CI
Motion for Asset Sale Filed by Endo International plc	22-11-22	CI
Motion for Asset Sale Approved for Endo International plc	22-10-27	CI
Motion for Asset Sale Filed by Endo International plc	22-09-22	CI
Motion for De Minimis Assets Sale Filed by Endo International plc	22-09-02	CI
Motion for Joint Administration Approved for Endo International plc	22-08-17	CI
Motion for Joint Administration Filed by Endo International plc	22-08-16	CI
Endo International plc Filed for Bankruptcy	22-08-16	CI
BioSpecifics Technologies Corp. Announces Management Changes	20-12-02	CI
BioSpecifics Technologies Corp.(NasdaqGM:BSTC) dropped from S&P Global BMI Index	20-12-02	CI
BioSpecifics Technologies Corp.(NasdaqGM:BSTC) dropped from S&P TMI Index	20-12-02	CI
BioSpecifics Technologies Corp.(NasdaqGM:BSTC) dropped from Russell 2500 Index	20-12-02	CI
BioSpecifics Technologies Corp.(NasdaqGM:BSTC) dropped from Russell Small Cap Comp Growth Index	20-12-02	CI

Chart BioSpecifics Technologies Corp.

Duration

Period

More charts

Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-3.99%	21.28B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B
LEGEND BIOTECH CORPORATION	-28.60%	7.83B

Bio Therapeutic Drugs